Drug Profile
RX 10045
Alternative Names: RvE1 synthetic analogue; RX-10045Latest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Resolvyx Pharmaceuticals
- Developer Auven Therapeutics; Resolvyx Pharmaceuticals
- Class Anti-inflammatories; Eye disorder therapies; Omega 3 fatty acids; Small molecules
- Mechanism of Action Inflammation mediator inhibitors; Lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Age-related macular degeneration; Allergic conjunctivitis; Diabetic macular oedema; Dry eyes; Postoperative inflammation; Postoperative pain; Retinal disorders
Most Recent Events
- 22 Feb 2023 Discontinued - Phase-I for Retinal disorders in USA (Ophthalmic)
- 22 Feb 2023 Discontinued - Phase-II for Allergic conjunctivitis in USA (Ophthalmic)
- 22 Feb 2023 Discontinued - Phase-II for Dry eyes in USA (Ophthalmic)